NASDAQ · Healthcare Plans · USD
Alignment Healthcare, Inc. (ALHC) Stock Analysis
Alignment Healthcare, Inc. (ALHC) is a Healthcare Plans stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ALHC Key Statistics
As of Sep 4, 2026Trading
- Open
- $13.34
- Previous Close
- $13.55
- Day's Range
- 13.16–13.58
- 52-Week Range
- 12.70–25.12
- Volume
- 5.10M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.11
Valuation
- Market Cap
- $2.81B
- P/E Ratio
- 71.26
- Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
- 17.99
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 0.61
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 0.19
Financials (FY)
- Revenue (FY)
- $3.95B+46.06%
- Net Income (FY)
- −$724.00K
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.89%
- Shares Outstanding
- 207.44M
- 1-Year Return
- −16.93%
Dividend and dates
- Earnings Date
- October 29, 2026
- Avg Volume
- 5.42M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
ALHC Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −31.44% |
| 2025 | +75.56% |
| 2024 | +30.66% |
| 2023 | −26.79% |
| 2022 | −16.36% |
| 2021 (partial year) | −18.78% |
As of September 4, 2026.
ALHC Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $3.95B | −$724.00K | −0.0% |
| 2024 | $2.70B | −$128.04M | −4.7% |
| 2023 | $1.82B | −$148.02M | −8.1% |
| 2022 | $1.43B | −$149.55M | −10.4% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $3.95B | $488.56M | $14.75M | −$724.00K | −0.0% |
| 2024 | $2.70B | $296.69M | −$101.56M | −$128.04M | −4.7% |
| 2023 | $1.82B | $201.03M | −$127.82M | −$148.02M | −8.1% |
| 2022 | $1.43B | $184.28M | −$128.64M | −$149.55M | −10.4% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ALHC Valuation vs Healthcare Plans Median
Median of 11 stocks| Metric | ALHC | Healthcare Plans median | vs median |
|---|---|---|---|
| P/E | 71.26 | 25.66 | 178% above |
| P/S ratio | 0.61 | 0.44 | 40% above |
| Profit margin | 0.89% | 1.18% | 0.3 pts below |
Medians across 11 Healthcare Plans stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Alignment Healthcare to Present in Baird 2026 Global Healthcare Conference and Attend Morgan Stanley 24th Annual Global Healthcare Conference
YahooAlignment Healthcare: The Drawdown I Told You To Wait For Has Arrived (Rating Upgrade)
SeekingAlphaJP Morgan Maintains Overweight on Alignment Healthcare, Lowers Price Target to $22
BenzingaRaymond James Downgrades Alignment Healthcare to Outperform, Lowers Price Target to $19
BenzingaAlignment Healthcare, Inc. (ALHC) Q2 2026 Earnings Call Transcript
SeekingAlphaAlignment Healthcare (NASDAQ:ALHC) Beats Q2 Earnings but Guidance Miss Sends Shares Tumbling
ChartMill
All 9 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Healthcare Plans Stocks
UnitedHealth Group Incorporated
$356.47B
CVSCVS Health Corporation
$123.73B
ELVElevance Health, Inc.
$88.37B
CIThe Cigna Group
$74.65B
HUMHumana Inc.
$48.22B
CNCCentene Corporation
$33.12B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
NVSNovartis AG
$304.10B






